Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML
SUPPLEMENTARY MATERIALS

Clinical trials
The clinical trials were approved by the Indiana University Institutional Review Board. Clinical outcomes analysis was performed by Drs. Sayar, Abu Zaid, and Boswell, and the information was available to all the collaborators.
Protocol synopses
Patients with relapsed/refractory AML, or primary diagnoses occurring in elderly patients (=/>70 years), were treated on consecutive phase I studies, following informed consent according to standard guidelines of the Helsinki Declaration.
Phase I, Open-label, Dose- 
Primary outcome measures:
Determine the maximum tolerated dose of a combination of Sorafenib and Vorinostat administered to patients with poor-risk AML, or MDS with >10% blasts: Baseline through cycle 3
Secondary outcome measures:
Evaluate response and the duration of response to this combination targeted therapy Evaluate the toxicity of the combination
Exploratory objective
To explore the mechanistic attributes for efficacy of this combination in AML with respect to expression of a panel of prognostic genes including c-jun, stat5, and NFkB 
Primary outcome measures:
Number of dose limiting toxicities (DLTs) after administration of sorafenib, vorinostat and bortezomib
Secondary outcome measures:
Number of patients with a partial response or greater to the combination of sorafenib, vorinostat and bortezomib of treatment ]
Duration to relapse in patients who experience relapse following achievement of a complete remission. This is defined as the duration of remission from the time of documentation of complete morphologic remission to the time of documentation of relapse.
Exploratory objective:
To explore the mechanistic attributes for efficacy of this combination in AML with complex-or poor-risk (monosomy 5/7)-cytogenetics or FLT3-ITD positive genotype.
Outcomes. Toxicity was recorded for the two trials as noted above. In the first trial, a total of 15 patients were enrolled with intent to treat, and 3 dose levels were assigned. 13 patients completed at least 1 cycle of therapy (one patient withdrew and another failed to complete). The 3 patient cohorts were treated as following: Sorafenib 400 mg twice daily in all cohorts.
Vorinostat -100 mg twice daily in cohort 1; 200 mg in AM and 100 mg in PM in cohort 2; 200 mg twice daily in cohort 3. No DLT was observed in the first two cohorts. One/six patient in the 3 rd cohort developed grade 4 diarrhea in the setting of neutropenic fever. A maximum tolerated dose (MTD) was not achieved in the study, but an optimal dose was determined as that dosing achieved in cohort 3.
In the second trial, which involved integration of Bortezomib into the first trial's optimal dosing for Sorafenib and Vorinostat, required initial recission of optimal dosing achieved above, followed by stepwise escalation to avoid DLTs:
Dosing levels The response/efficacy measures of the two trials are reported, respectively, in Supplementary Tables 1 and 2 
